Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
Ainos (NASDAQ:AIMD) has secured a significant Japanese patent (No. 7619659) for VELDONA®, its innovative oral interferon formulation designed to treat and prevent coronavirus infections. This follows a recent patent approval in Taiwan, strengthening the company's global IP portfolio in a market projected to exceed $16 billion by 2031.
The patent includes 15 key claims covering VELDONA's formulation, featuring low-dose administration under 1,000 IU, sublingual and buccal delivery mechanisms, and flexible dosage forms. Unlike traditional interferon therapies, VELDONA® doesn't require cold chain logistics, significantly reducing costs.
The technology offers dual benefits for coronavirus treatment and prevention, with proven broad-spectrum antiviral efficacy against multiple variants. VELDONA® addresses accessibility through non-invasive oral therapy, affordability by eliminating cold chain dependency, and enhanced safety through its low-dose formulation.
Ainos (NASDAQ:AIMD) ha acquisito un importante brevetto giapponese (n. 7619659) per VELDONA®, la sua innovativa formulazione di interferone orale progettata per trattare e prevenire le infezioni da coronavirus. Questo segue l'approvazione recente di un brevetto a Taiwan, rafforzando il portafoglio globale di proprietà intellettuale dell'azienda in un mercato previsto in crescita oltre 16 miliardi di dollari entro il 2031.
Il brevetto include 15 rivendicazioni chiave che coprono la formulazione di VELDONA, con una somministrazione a basso dosaggio sotto 1.000 IU, meccanismi di somministrazione sublinguale e buccale, e forme di dosaggio flessibili. A differenza delle terapie tradizionali con interferone, VELDONA® non richiede logistica a catena del freddo, riducendo significativamente i costi.
La tecnologia offre doppi vantaggi per il trattamento e la prevenzione del coronavirus, con comprovata efficacia antivirale ad ampio spettro contro diversi varianti. VELDONA® affronta l'accessibilità attraverso una terapia orale non invasiva, l'affordabilità eliminando la dipendenza dalla catena del freddo, e la maggiore sicurezza grazie alla sua formulazione a basso dosaggio.
Ainos (NASDAQ:AIMD) ha asegurado una patente japonesa significativa (número 7619659) para VELDONA®, su innovadora formulación de interferón oral diseñada para tratar y prevenir infecciones por coronavirus. Esto sigue a una reciente aprobación de patente en Taiwán, fortaleciendo el portafolio global de propiedad intelectual de la empresa en un mercado proyectado a superar los 16 mil millones de dólares para 2031.
La patente incluye 15 reivindicaciones clave que cubren la formulación de VELDONA, con administración de baja dosis por debajo de 1,000 IU, mecanismos de entrega sublinguales y bucales, y formas de dosificación flexibles. A diferencia de las terapias tradicionales con interferón, VELDONA® no requiere logística en cadena de frío, lo que reduce significativamente los costos.
La tecnología ofrece beneficios duales para el tratamiento y la prevención del coronavirus, con eficacia antiviral de amplio espectro comprobada contra múltiples variantes. VELDONA® aborda la accesibilidad a través de una terapia oral no invasiva, la asequibilidad al eliminar la dependencia de la cadena de frío, y una mayor seguridad gracias a su formulación de baja dosis.
Ainos (NASDAQ:AIMD)는 코로나바이러스 감염 치료 및 예방을 위해 설계된 혁신적인 경구 인터페론 제형인 VELDONA®에 대해 중요한 일본 특허(번호 7619659)를 확보했습니다. 이는 대만에서의 최근 특허 승인에 이어진 것으로, 2031년까지 160억 달러를 초과할 것으로 예상되는 시장에서 회사의 글로벌 지적 재산권 포트폴리오를 강화하고 있습니다.
이번 특허는 1,000 IU 이하의 저용량 투여, 설하 및 구강 전달 메커니즘, 유연한 용량 형태를 특징으로 하는 VELDONA의 제형을 포함한 15개의 주요 청구를 포함하고 있습니다. 전통적인 인터페론 치료와 달리, VELDONA®는 냉장 유통이 필요하지 않아 비용을 상당히 줄입니다.
이 기술은 코로나바이러스 치료 및 예방을 위한 이중 이점을 제공하며, 여러 변종에 대한 광범위한 항바이러스 효능이 입증되었습니다. VELDONA®는 비침습적인 경구 요법을 통해 접근성을 높이고, 냉장 유통 의존성을 없애 가격을 저렴하게 하며, 저용량 제형으로 안전성을 향상시킵니다.
Ainos (NASDAQ:AIMD) a obtenu un brevet japonais significatif (n° 7619659) pour VELDONA®, sa formulation innovante d'interféron oral conçue pour traiter et prévenir les infections à coronavirus. Cela fait suite à une récente approbation de brevet à Taïwan, renforçant le portefeuille mondial de propriété intellectuelle de l'entreprise sur un marché prévu à dépasser 16 milliards de dollars d'ici 2031.
Le brevet comprend 15 revendications clés couvrant la formulation de VELDONA, avec une administration à faible dose inférieure à 1 000 UI, des mécanismes de délivrance sublinguale et buccale, et des formes de dosage flexibles. Contrairement aux thérapies traditionnelles à l'interféron, VELDONA® ne nécessite pas de logistique de chaîne du froid, réduisant ainsi considérablement les coûts.
La technologie offre des avantages doubles pour le traitement et la prévention des coronavirus, avec une efficacité antivirale à large spectre prouvée contre plusieurs variants. VELDONA® aborde l'accessibilité grâce à une thérapie orale non invasive, l'accessibilité en éliminant la dépendance à la chaîne du froid, et une sécurité accrue grâce à sa formulation à faible dose.
Ainos (NASDAQ:AIMD) hat ein bedeutendes japanisches Patent (Nr. 7619659) für VELDONA®, seine innovative orale Interferon-Formulierung zur Behandlung und Prävention von Coronavirus-Infektionen, gesichert. Dies folgt auf eine kürzliche Patenterteilung in Taiwan, die das globale geistige Eigentumsportfolio des Unternehmens in einem Markt stärkt, der voraussichtlich bis 2031 über 16 Milliarden Dollar hinausgehen wird.
Das Patent umfasst 15 wichtige Ansprüche, die die Formulierung von VELDONA abdecken, darunter die Verabreichung in niedriger Dosis unter 1.000 IU, sublinguale und bukale Abgabemechanismen sowie flexible Dosierungsformen. Im Gegensatz zu herkömmlichen Interferon-Therapien benötigt VELDONA® keine Kühlkette, was die Kosten erheblich senkt.
Die Technologie bietet doppelte Vorteile für die Behandlung und Prävention von Coronavirus, mit nachgewiesener breiter antiviraler Wirksamkeit gegen multiple Varianten. VELDONA® fördert die Zugänglichkeit durch nicht-invasive orale Therapie, bezahlbarkeit durch Eliminierung der Abhängigkeit von der Kühlkette und verbesserte Sicherheit durch seine Niedrigdosis-Formulierung.
- Secured Japanese patent approval for VELDONA®, expanding global IP protection
- Targeting $16 billion coronavirus therapeutics market by 2031
- Cost-effective solution eliminating cold chain logistics requirements
- Versatile application potential beyond coronavirus, including autoimmune diseases
- Product still requires further clinical validation and regulatory approvals
- Faces competition in a crowded coronavirus therapeutics market
Insights
The Japanese patent approval for VELDONA represents a significant milestone in antiviral therapeutics, particularly in the evolving $16 billion coronavirus market. The technology's key differentiator lies in its novel sublingual delivery system, which addresses major limitations of traditional interferon therapies.
The patent's technical specifications reveal important advantages:
- Sub-1000 IU dosing suggests superior safety profile while maintaining efficacy
- Room-temperature stability eliminates cold chain requirements, potentially reducing distribution costs by
40-60% - Multiple delivery formats (lozenges, tablets, films, sprays) enable market segmentation and broader adoption
From a market perspective, VELDONA's positioning is strategically sound. Current antiviral treatments face challenges with viral mutations, cost constraints and administration complexity. The oral delivery platform could significantly expand the addressable market, particularly in regions with healthcare infrastructure.
Looking ahead, several key catalysts could drive value:
- Potential fast-track regulatory pathways given the persistent coronavirus threat
- Expansion opportunities beyond coronavirus into autoimmune and other viral indications
- Additional patent applications in other major markets strengthening global IP protection
However, investors should monitor:
- Timeline to commercialization and regulatory requirements
- Manufacturing scale-up capabilities
- Competitive landscape evolution, particularly from other novel antiviral approaches
The Japanese patent approval materially enhances Ainos' commercial prospects in the $16 billion coronavirus therapeutics market. The elimination of cold chain requirements presents a compelling economic advantage, potentially yielding
Key financial implications include:
- Reduced manufacturing complexity and storage costs
- Enhanced distribution economics, particularly in emerging markets
- Multiple revenue streams through various delivery formats
- Potential licensing opportunities in different territories
The company's strategic positioning is strengthened by:
- Comprehensive IP protection with 15 claims
- Scalable manufacturing potential
- Multiple market opportunities beyond coronavirus
Notably, the broad applicability across various immune-related conditions significantly expands the total addressable market. The combination of reduced operational costs and multiple revenue streams could drive substantial margin expansion as the company scales.
Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the
SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") proudly announces the granting of a pivotal invention patent in Japan (Patent No. 7619659) for its groundbreaking oral interferon formulation, VELDONA®, to treat and prevent coronavirus infections. Following the recent patent approval in Taiwan, this Japanese patent strengthens Ainos' global intellectual property (IP) portfolio and establishes the Company as a leader in differentiated antiviral solutions.
The global coronavirus therapeutics market is projected to exceed
Key Patent Highlights and Technical Innovations
The newly granted patent includes 15 key claims that deliver comprehensive protection for VELDONA®, covering its formulation, novel sublingual and buccal delivery mechanisms, and broad therapeutic applications. The patented features emphasize:
• Low-Dose Administration: Using doses under 1,000 IU to optimize efficacy and minimize side effects.
• Innovative Delivery Mechanisms: Sublingual and buccal absorption for rapid action and enhanced bioavailability, eliminating the need for injections.
• Flexible Dosage Forms: Includes lozenges, tablets, films, and sprays, offering greater convenience for patients.
• No Cold Chain Requirements: Unlike traditional interferon therapies that rely on costly cold chain logistics, VELDONA®'s oral formulation significantly reduces logistical and operational costs.
"This patent represents a significant breakthrough for interferon-based therapies. With patents already granted in Taiwan and Japan, and additional applications underway in other countries, we are reinforcing our global IP portfolio and advancing our commercialization strategy in a multi-billion-dollar market," said Chun-Hsien (Eddy) Tsai, Chairman and CEO of Ainos.
A Differentiated Solution for a Persistent Challenge
As coronavirus continues to mutate and pose long-term threats to global health, VELDONA® offers dual benefits:
1. Treatment: Proven broad-spectrum antiviral efficacy against multiple coronavirus variants.
2. Prevention: Potential to strengthen immune defenses and reduce susceptibility to new infections.
VELDONA® addresses critical gaps in current treatment options, including:
• Accessibility: A patient-friendly, non-invasive oral therapy.
• Affordability: Eliminates the dependency on expensive cold chain logistics, ensuring cost-effective global distribution.
• Safety: A low-dose formulation with minimal side effects compared to traditional interferon treatments.
"With VELDONA®, we're setting a new standard for innovation in antiviral therapies," added Tsai. "Our solution combines cutting-edge science with practical advantages, offering a competitive edge that positions Ainos as a global leader in antiviral innovation."
Expanding Beyond Coronavirus
Beyond its role in addressing coronavirus infections, VELDONA® has demonstrated potential applications across a wide range of immune-related conditions, including autoimmune diseases, and other viral infections. Its flexibility and adaptability highlight its potential to transform therapeutic approaches in multiple medical fields.
Ainos' Vision for Global Health
With nearly 40 years of research and development, Ainos has consistently driven innovation in antiviral technologies. VELDONA® exemplifies the Company's commitment to delivering differentiated, cost-effective solutions that address critical public health challenges.
Dr. Albert Yu, Technical Director of Pharmaceuticals at Ainos, remarked: "This patent is not just a validation of our innovation but also a significant milestone in our journey to combat global health threats. We look forward to VELDONA®'s broad clinical applications and its ability to benefit patients worldwide."
Ainos asserts that the coronavirus will persist as a long-term global health challenge. The Company is committed to providing accessible, scalable solutions to protect human health, mitigate the virus's impact, and improve global immunity.
With its high efficacy, minimal side effects, and scalable design, VELDONA® is positioned as the next-generation antiviral solution. Ainos will continue to advance antiviral technologies and set new benchmarks in global health innovation
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the market potential for Ainos (AIMD) VELDONA technology?
What are the key features of AIMD's VELDONA patent approved in Japan?
How does AIMD's VELDONA differ from traditional interferon treatments?
What therapeutic applications does AIMD's VELDONA target?
Which countries have granted patents for AIMD's VELDONA technology?
